HemaSphere (Jun 2022)

S183: NOVEL COMBINATION IMMUNOTHERAPY FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS FOR TALQUETAMAB (A GPRC5D X CD3 BISPECIFIC ANTIBODY) IN COMBINATION WITH DARATUMUMAB

  • N. W. van de Donk,
  • N. Bahlis,
  • M.-V. Mateos,
  • K. Weisel,
  • B. Dholaria,
  • A. L. Garfall,
  • H. Goldschmidt,
  • T. G. Martin,
  • D. Morillo,
  • D. E. Reece,
  • D. Hurd,
  • P. Rodríguez-Otero,
  • M. Bhutani,
  • A. D’Souza,
  • A. Oriol,
  • E. Askari,
  • J. F. San-Miguel,
  • K. M. Kortüm,
  • D. Vishwamitra,
  • S. Xin Wang Lin,
  • T. J. Prior,
  • L. Vandenberk,
  • M.-A. D. Smit,
  • J. D. Goldberg,
  • R. Wäsch,
  • A. Chari

DOI
https://doi.org/10.1097/01.HS9.0000843624.82943.92
Journal volume & issue
Vol. 6
pp. 84 – 85

Abstract

Read online

No abstracts available.